G. Funk (Vienna, Austria), N. Miculinic (Zagreb, Croatia), B. Lamprecht (Salzburg, Austria), J. Wedzicha (London, United Kingdom)
LATE-BREAKING ABSTRACT: The role of modification of CURB-65 score as prediction factor for one year survival in acute exacerbation of COPD
W. Heru Wiyono, W. Sri Hastuti, Ratnawati, I. Gumiwang, J. Prihartono (Jakarta, Indonesia)
|   |
Densitometric diagnosis of osteoporosis in patients with chronic obstructive pulmonary disease
E. Kochetova (Petrozavodsk, Russian Federation)
| |
Is COPD a risk factor for diabetes?
L. Ciobanu, V. Maciuc, A. Cretu, G. Grigoras (Iasi, Romania)
| |
The relationship of comorbidities with clinical and phsyiological parameters in COPD
F. Ciftci, E. Sen, G. Arkan, D. Acar, P. Onen, B. Gulbay, O. Yildiz, T. Acican, S. Saryal, G. Karabiyikoglu (Ankara, Turkey)
| |
Bronchitic and non-bronchitic phenotypes of COPD differ in the prevalence of depressive symptoms
V. Koblizek, S. Pracharova, M. Hronek, M. Kovarik (Hradec Kralove, Czech Republic)
| |
Evaluation of association between COPD and metabolic syndrome, and insulin resistance
O.R. López Jové, E. López González, S. Rey, E. Giugno, V. Barrionuevo, A. Galdames, Y.F. Wu, S. Parissi, G. Tabaj (Buenos Aires, Argentina)
| |
The influence of metabolic syndrome in mortality rate of COPD patients: A five years follow up study
K. Schelini, S. Tanni, A. Zamuner, L. Coelho, S. Vale, R. Ferrari, L. Caram, I. Godoy, S. Paiva, I. Godoy (Botucatu, Brazil)
| |
COPD: Different psychology status (PS) in patients with different cardiac co-morbidities rate
K. Gashynova (Dnipropetrovsk, Ukraine)
| |
Pulmonary hypertension in COPD: Prevalence and characteristics
D. Gologanu, I. Ion, M. Balea, P. Leru, S. Caraiola, C. Stanescu (Bucharest, Romania)
| |
Cognitive function of patients with COPD after virtual admission – A randomized clinical trial
L. Schou, B. Østergaard, L. Rasmussen, S. Rydahl-Hansen, A. Svarre Jakobsen, C. Emme, K. Phanareth (Copenhagen, Odense, Denmark)
| |
Longitudinal changes in detrended fluctuation analysis "alpha" of PEF in COPD
G. Donaldson, T. Seemungal, J. Hurst, U. Frey, J. Wisia (London, United Kingdom; St. Augustine, Trinidad And Tobago; Basel, Switzerland)
| |
Anxiety and dyspnea relation in early stage COPD patients
L. Yilmaz Aydin, T. Ozdemir, S. Berik (Duzce, Corum, Turkey)
| |
Acute pulmonary embolism in COPD patients
D.A. Rodriguez, M. Orozco-Levi, A. Herranz, F. Miranda, A. Ramirez-Sarmiento, A. Rodo-Pin, N. Bas Costas, J. Martinez-llorens, J. Bruguera, J. Gea, L. Molina (Barcelona, Spain; Santander, Colombia)
| |
COPD subphenotypes in a population-based survey by factor and cluster analysis
N. Fens, A.G.J. van Rossum, P. Zanen, B. van Ginneken, R.J. van Klaveren, A.H. Zwinderman, P.J. Sterk (Utrecht, Nijmegen, Netherlands)
| |
NT-proBNP, troponin T and left ventricular function in patients with acute exacerbation of chronic obstructive pulmonary disease
M. Lainscak, R. Marcun, A. Sustic, P. Mesko Brguljan, M. Kosnik, S. Kadivec, J. Farkas (Golnik, Ljubljana, Slovenia; Rijeka, Croatia)
| |
Inflammatory markers in COPD patients with and without cachexia
S. Torres, M.E. Laucho, M. Montes de Oca, H. Liang, N. Musi (Caracas, Venezuela; San Antonio, United States Of America)
| |
The prevalence of undiagnosed COPD and approaches to promote early COPD diagnosis in lung cancer population
J. Zhang, J.B. Zhou, X.F. Lin, Q. Wang, C. Bai, Q.Y. Hong (Shanghai, China)
| |
The association between pulmonary arterial hypertension secondary to chronic lung disease and serum asymmetric dimethylarginine levels
B. Açikmese, G. Çamsari, A. Gür, N.D. Bakan, G. Özkan, P. Güven (Istanbul, Turkey)
| |
Pneumothorax secondary to chronic obstructive pulmonary disease
N. Fettal, A. Taleb (Sidi bel Abbes, Algeria)
| |
Endocrinopathies and related with COPD exacerbation
T. Korlu, M. Nuzumlali, S. Nazik, N. Kokturk (Ankara, Turkey)
| |